VERAXA combines game changing technologies to solve the most prominent challenges in antibody drug development.
VERAXA efficiently finds functional monoclonal antibodies (mAbs) – out of entire immune repertoires with several million B cells – in less than 48 hours. In contrast to most common approaches, we directly assess and quantify intracellular signal modulations induced by functional antibodies in one single analytical screening step under High Throughput Screening (HTS) conditions. Our proprietary microfluidic-based technology enables fully quantitative readouts for hundreds of B-cells per second with separation of all functional hits for sequencing and further development. VERAXA technology avoids cumbersome, diversity-reducing and error prone two-step processes in functional antibody identification.
Chemical labeling of antibodies with different payloads can sharpen the desired target drug profile. VERAXA has developed superior antibody labeling technologies that allow conjugation of any given antibody at almost every position with highest reproducibility and the fastest bioorthogonal chemistry available today.
By partnering with VERAXA, pharma clients will get rare and otherwise difficult to find functional hits in much shorter times, thus significantly de-risking their entire preclinical development path.
Therapeutic functional antibodies that are needed for the specific modulation of pathologically dysregulated receptor-associated signaling are rare, difficult to find and belong to the most precious pharmaceutical agents with enormous market potentials.
VERAXA is the leading partner for the biopharmaceutical industry to screen, identify and engineer functional therapeutic antibodies for an accelerated and de-risked drug development process. The company’s proprietary and unique droplet-based microfluidic technology and its superior functional cellular assay systems allow for a direct assessment and screening for functional antibody hits in one single screening round. Thus, VERAXA directly unravels – like no other company – the full functional and therapeutic potential of entire immune systems even on complicated signal receptors like G protein-coupled receptors (GPCRs) in a very short time and at unmet efficiency.